BioSpace News Archive

Inspirna, Inc.announced today a licensing agreement with Merck KGaA, Darmstadt, Germany, for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic colorectal cancer (mCRC) and SLC6a8 targeting follow-on compounds.

Earlier this year, scientists unveiled the first draft of the pangenome, based on full genetic blueprints from 47 people around the world to create a more diverse representation of the human genome.

Kineta, Inc. announced that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week.

Alamar Biosciences announced the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq Inflammation Panel 250 for deep profiling of immune response.

OSI Systems, Inc. announced that its Healthcare division, Spacelabs Healthcare®, has received an order valued at approximately $5 million to provide patient monitoring solutions and related supplies and accessories to a U.S. based hospital.

JW Therapeutics (HKEx: 2126) announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (r/r MCL).

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, highlighted the Company’s strategic priorities and anticipated milestones for 2024.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 11:15 a.m. Pacific Time.

ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that it will be presenting at the 42nd annual J.P. Morgan Healthcare Conference.

Lexaria Bioscience Corp. (NASDAQ:LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces positive final results from its recently completed human Pilot Study #1 (the “Study”) evaluating DehydraTECHTM technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1") drug semaglutide available commercially in the branded product Rybelsus®.